Polymeric nanoparticles affect the intracellular delivery, antiretroviral activity and cytotoxicity of the microbicide drug candidate dapivirine

Pharmaceutical Research

Volumn 29, Issue 6, 2012, Pages 1468-1484

  Das Neves, José ^a   Michiels, Johan ^b   Ariën, Kevin K ^b   Vanham, Guido ^b,c,d   Amiji, Mansoor ^e   Bahia, Maria Fernanda ^a   Sarmento, Bruno ^a,f  

^a UNIVERSITY OF PORTO   (Portugal)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d FREE UNIVERSITY OF BRUSSELS   (Belgium)

^e NORTHEASTERN UNIVERSITY   (United States)

^f UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

Author keywords

cell uptake; HIV AIDS; microbicides; nanotechnology; poly( caprolactone)

Indexed keywords

CETRIMIDE; DAPIVIRINE; DODECYL SULFATE SODIUM; POLOXAMER; POLYCAPROLACTONE;

ANTIVIRAL ACTIVITY; ARTICLE; CELL TYPE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG SELECTIVITY; DRUG UPTAKE; EPITHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; PARTICLE SIZE; PH; PHAGOCYTE; PRIORITY JOURNAL; SURFACE PROPERTY; VAGINA;

ANIMALS; ANTI-HIV AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; CETRIMONIUM COMPOUNDS; CHEMISTRY, PHARMACEUTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG COMPOUNDING; EPITHELIAL CELLS; FEMALE; HELA CELLS; HIV-1; HUMANS; KINETICS; MICE; NANOPARTICLES; NANOTECHNOLOGY; POLOXAMER; POLYESTERS; PYRIMIDINES; SODIUM DODECYL SULFATE; SOLUBILITY; SURFACE PROPERTIES; SURFACE-ACTIVE AGENTS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84862687804     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-011-0622-3     Document Type: Article

References (55)

1. MS Cohen N Hellmann JA Levy K DeCock J Lange 2008 The spread, treatment, and prevention of HIV-1: evolution of a global pandemic J Clin Invest 118 4 1244 1254 18382737 10.1172/JCI34706 1:CAS:528:DC%2BD1cXkt1CntLo%3D
2. RM Grant JR Lama PL Anderson V McMahan AY Liu L Vargas, et al. 2010 Preexposure chemoprophylaxis for HIV prevention in men who have sex with men N Engl J Med 363 27 2587 2599 21091279 10.1056/NEJMoa1011205 1:CAS:528: DC%2BC3MXit1ansg%3D%3D
3. GC Morris CJ Lacey 2010 Microbicides and HIV prevention: lessons from the past, looking to the future Curr Opin Infect Dis 23 1 57 63 19918175 10.1097/QCO.0b013e328334de6d
4. Q Abdool Karim SS Abdool Karim JA Frohlich AC Grobler C Baxter LE Mansoor, et al. 2010 Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science. 329 5996 1168 1174 20643915 10.1126/science.1193748 1:CAS:528:DC%2BC3cXhtV2hsr%2FI
5. KK Ariën G Vanham 2010 First real success for anti-HIV gel: a new start for HIV microbicides? Future Microbiol 5 1621 1623 21133683 10.2217/fmb.10.129
6. F Hladik MJ McElrath 2008 Setting the stage: host invasion by HIV Nat Rev Immunol 8 6 447 457 18469831 10.1038/nri2302 1:CAS:528:DC%2BD1cXmt1Ojtrg%3D
7. R Shen HE Richter RH Clements L Novak K Huff D Bimczok, et al. 2009 Macrophages in vaginal but not intestinal mucosa are monocyte-like and permissive to human immunodeficiency virus type 1 infection J Virol 83 7 3258 3267 19153236 10.1128/JVI.01796-08 1:CAS:528:DC%2BD1MXjs1Wrt7c%3D
8. KK Ariën V Jespers G Vanham 2011 HIV sexual transmission and microbicides Rev Med Virol 21 2 110 133 10.1002/rmv.684
9. Kashuba AD, Abdool Karim SS, Kraft E, White N, Sibeko S, Werner L, et al. Do systemic and genital tract tenofovir concentrations predict HIV seroconversion in the CAPRISA 004 tenofovir gel trial? XVIII International AIDS Conference, 2010, Vienna, Austria.
10. LC Rohan AB Sassi 2009 Vaginal drug delivery systems for HIV prevention AAPS J 11 1 78 87 19194802 10.1208/s12248-009-9082-7 1:CAS:528: DC%2BD1MXhtVWru7fJ
11. LC du Toit V Pillay YE Choonara 2010 Nano-microbicides: challenges in drug delivery, patient ethics and intellectual property in the war against HIV/AIDS Adv Drug Deliv Rev. 62 4-5 532 546 19922751 10.1016/j.addr.2009.11.022
12. J das Neves MM Amiji MF Bahia B Sarmento 2010 Nanotechnology-based systems for the treatment and prevention of HIV/AIDS Adv Drug Deliv Rev. 62 4-5 458 477 19914314 10.1016/j.addr.2009.11.017
13. R Mallipeddi LC Rohan 2010 Nanoparticle-based vaginal drug delivery systems for HIV prevention Expert Opin Drug Deliv. 7 1 37 48 20017659 10.1517/17425240903338055 1:CAS:528:DC%2BD1MXhsFOnsL%2FE
14. AS Ham MR Cost AB Sassi CS Dezzutti LC Rohan 2009 Targeted delivery of PSC-RANTES for HIV-1 prevention using biodegradable nanoparticles Pharm Res 26 3 502 511 19002569 10.1007/s11095-008-9765-2 1:CAS:528:DC%2BD1cXhtlGgtr7F
15. KA Woodrow Y Cu CJ Booth JK Saucier-Sawyer MJ Wood WM Saltzman 2009 Intravaginal gene silencing using biodegradable polymer nanoparticles densely loaded with small-interfering RNA Nat Mater 8 6 526 533 19404239 10.1038/nmat2444 1:CAS:528:DC%2BD1MXmtFems7Y%3D
16. JS Chawla MM Amiji 2002 Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen Int J Pharm 249 1-2 127 138 12433441 10.1016/S0378-5173(02)00483-0 1:CAS:528:DC%2BD38XosFagu74%3D
17. LK Shah MM Amiji 2006 Intracellular delivery of saquinavir in biodegradable polymeric nanoparticles for HIV/AIDS Pharm Res 23 11 2638 2645 16969696 10.1007/s11095-006-9101-7 1:CAS:528:DC%2BD28XhtFKgu7nP
18. D Ece Gamsiz LK Shah H Devalapally MM Amiji RL Carrier 2008 A model predicting delivery of saquinavir in nanoparticles to human monocyte/macrophage (Mo/Mac) cells Biotechnol Bioeng. 101 5 1072 1082 18553495 10.1002/bit.21958 1:STN:280:DC%2BD1cnoslWkug%3D%3D
19. J das Neves B Sarmento MM Amiji MF Bahia 2010 Development and validation of a rapid reversed-phase HPLC method for the determination of the non-nucleoside reverse transcriptase inhibitor dapivirine from polymeric nanoparticles J Pharm Biomed Anal. 52 2 167 172 20117900 10.1016/j.jpba.2010.01. 007
20. DH Owen DF Katz 1999 A vaginal fluid simulant Contraception 59 2 91 95 10361623 10.1016/S0010-7824(99)00010-4 1:CAS:528:DyaK1MXjvVeju70%3D
21. YV Frenkel AD Clark Jr K Das YH Wang PJ Lewi PA Janssen, et al. 2005 Concentration and pH dependent aggregation of hydrophobic drug molecules and relevance to oral bioavailability J Med Chem 48 6 1974 1983 15771441 10.1021/jm049439i 1:CAS:528:DC%2BD2MXhs1CqtLY%3D
22. M Cavrois J Neidleman JF Kreisberg WC Greene 2007 In vitro derived dendritic cells trans-infect CD4 T cells primarily with surface-bound HIV-1 virions PLoS Pathog. 3 1 e4 17238285 10.1371/journal.ppat.0030004
23. G Vanham L Penne H Allemeersch L Kestens B Willems G van der Groen, et al. 2000 Modeling HIV transfer between dendritic cells and T cells: importance of HIV phenotype, dendritic cell-T cell contact and T-cell activation AIDS 14 15 2299 2311 11089618 10.1097/00002030-200010200-00011 1:STN:280: DC%2BD3M7ltFGisQ%3D%3D
24. Y Van Herrewege L Penne C Vereecken K Fransen G van der Groen L Kestens, et al. 2002 Activity of reverse transcriptase inhibitors in monocyte-derived dendritic cells: a possible in vitro model for postexposure prophylaxis of sexual HIV transmission AIDS Res Hum Retroviruses. 18 15 1091 1102 12396448 10.1089/088922202320567833
25. Y Van Herrewege G Vanham J Michiels K Fransen L Kestens K Andries, et al. 2004 A series of diaryltriazines and diarylpyrimidines are highly potent nonnucleoside reverse transcriptase inhibitors with possible applications as microbicides Antimicrob Agents Chemother 48 10 3684 3689 15388420 10.1128/AAC.48.10.3684-3689.2004
26. F Sallusto A Lanzavecchia 1994 Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha J Exp Med. 179 4 1109 1118 8145033 10.1084/jem.179.4.1109 1:CAS:528:DyaK2cXhs1Wjurg%3D
27. Freshney RI. Culture of animal cells: a manual of basic technique and specialized applications. 6th ed. Hoboken: Wiley-Blackwell; 2010. p. 365-82.
28. Y Van Herrewege J Michiels J Van Roey K Fransen L Kestens J Balzarini, et al. 2004 In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides Antimicrob Agents Chemother 48 1 337 339 14693562 10.1128/AAC.48.1.337-339.2004
29. Y Gali O Delezay J Brouwers N Addad P Augustijns T Bourlet, et al. 2010 In vitro evaluation of viability, integrity and inflammation in genital epithelia upon exposure to pharmaceutical excipients and candidate microbicides Antimicrob Agents Chemother 54 12 5105 5114 20921308 10.1128/AAC.00456-10 1:CAS:528:DC%2BC3cXhsF2nu7bN
30. Y Kanemura H Mori S Kobayashi O Islam E Kodama A Yamamoto, et al. 2002 Evaluation of in vitro proliferative activity of human fetal neural stem/progenitor cells using indirect measurements of viable cells based on cellular metabolic activity J Neurosci Res 69 6 869 879 12205680 10.1002/jnr.10377 1:CAS:528:DC%2BD38XntFGntbc%3D
31. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol. 2005;Chapter 12:Unit 12.11.
32. DC Montefiori 2009 Measuring HIV neutralization in a luciferase reporter gene assay Methods Mol Biol. 485 395 405 19020839 10.1007/978-1-59745-170-3-26 1:CAS:528:DC%2BD1MXhsV2ksbY%3D
33. L Heyndrickx T Vermoesen K Vereecken J Kurth S Coppens L Aerts, et al. 2008 Antiviral compounds show enhanced activity in HIV-1 single cycle pseudovirus assays as compared to classical PBMC assays J Virol Methods. 148 1-2 166 173 18192031 10.1016/j.jviromet.2007.11.009 1:CAS:528:DC%2BD1cXisVSltLw%3D
34. Y Gali KK Ariën M Praet R Van den Bergh M Temmerman O Delezay, et al. 2010 Development of an in vitro dual-chamber model of the female genital tract as a screening tool for epithelial toxicity J Virol Methods. 165 2 186 197 20138087 10.1016/j.jviromet.2010.01.018 1:CAS:528:DC%2BC3cXksVaqurY%3D
35. VR Sinha K Bansal R Kaushik R Kumria A Trehan 2004 Poly-epsilon- caprolactone microspheres and nanospheres: an overview Int J Pharm 278 1 1 23 15158945 10.1016/j.ijpharm.2004.01.044 1:CAS:528:DC%2BD2cXktFOit7c%3D
36. MA Woodruff DW Hutmacher 2010 The return of a forgotten polymer-polycaprolactone in the 21st century Prog Polym Sci 35 10 1217 1256 10.1016/j.progpolymsci.2010.04.002 1:CAS:528:DC%2BC3cXht1eku7fK
37. SD Conner SL Schmid 2003 Regulated portals of entry into the cell Nature 422 6927 37 44 12621426 10.1038/nature01451 1:CAS:528:DC%2BD3sXhs1yit7Y%3D
38. SK Lai DE O'Hanlon S Harrold ST Man YY Wang R Cone, et al. 2007 Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus Proc Natl Acad Sci U S A 104 5 1482 1487 17244708 10.1073/pnas.0608611104 1:CAS:528:DC%2BD2sXhslans7Y%3D
39. AD Woolfson RK Malcolm RJ Morrow CF Toner SD McCullagh 2006 Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide Int J Pharm 325 1-2 82 89 16884869 10.1016/j.ijpharm.2006.06.026 1:CAS:528:DC%2BD28XhtFSgsrbP
40. KM Gupta SM Pearce AE Poursaid HA Aliyar PA Tresco MA Mitchnik, et al. 2008 Polyurethane intravaginal ring for controlled delivery of dapivirine, a nonnucleoside reverse transcriptase inhibitor of HIV-1 J Pharm Sci 97 10 4228 4239 18338805 10.1002/jps.21331 1:CAS:528:DC%2BD1cXht1Sgt7rF
41. O Harush-Frenkel E Rozentur S Benita Y Altschuler 2008 Surface charge of nanoparticles determines their endocytic and transcytotic pathway in polarized MDCK cells Biomacromolecules 9 2 435 443 18189360 10.1021/bm700535p 1:CAS:528:DC%2BD1cXlsl2htA%3D%3D
42. O Harush-Frenkel Y Altschuler S Benita 2008 Nanoparticle-cell interactions: drug delivery implications Crit Rev Ther Drug Carrier Syst. 25 6 485 544 19166392 1:CAS:528:DC%2BD1MXitFCrtb0%3D
43. C He Y Hu L Yin C Tang C Yin 2010 Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles Biomaterials 31 13 3657 3666 20138662 10.1016/j.biomaterials.2010.01.065 1:CAS:528:DC%2BC3cXisFSltrg%3D
44. D Bazile C Prud'homme MT Bassoullet M Marlard G Spenlehauer M Veillard 1995 Stealth Me.PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system J Pharm Sci. 84 4 493 498 7629743 10.1002/jps.2600840420 1:CAS:528:DyaK2MXkvVCmtr0%3D
45. J Panyam V Labhasetwar 2003 Dynamics of endocytosis and exocytosis of poly(D, L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells Pharm Res 20 2 212 220 12636159 10.1023/A:1022219003551 1:CAS:528: DC%2BD3sXpslWisw%3D%3D
46. P Lewi E Arnold K Andries H Bohets H Borghys A Clark, et al. 2004 Correlations between factors determining the pharmacokinetics and antiviral activity of HIV-1 non-nucleoside reverse transcriptase inhibitors of the diaryltriazine and diarylpyrimidine classes of compounds Drugs R D. 5 5 245 257 15357624 10.2165/00126839-200405050-00001 1:CAS:528:DC%2BD2cXpvFOitro%3D
47. H Tajalli A Ghanadzadeh Gilani MS Zakerhamidi M Moghadam 2009 Effects of surfactants on the molecular aggregation of rhodamine dyes in aqueous solutions Spectrochim Acta A Mol Biomol Spectrosc. 72 4 697 702 19147398 10.1016/j.saa.2008.09.033 1:STN:280:DC%2BD1M7ivVKrsg%3D%3D
48. FL Arbeloa PR Ojeda IL Arbeloa 1988 Dimerization and trimerization of rhodamine 6G in aqueous solution. Effect on the fluorescence quantum yield J Chem Soc [Perkin 1] 84 12 1903 1912
49. K Terrazas-Aranda Y Van Herrewege PJ Lewi J Van Roey G Vanham 2007 In vitro pre- and post-exposure prophylaxis using HIV inhibitors as microbicides against cell-free or cell-associated HIV-1 infection Antivir Chem Chemother 18 3 141 151 17626598 1:CAS:528:DC%2BD2sXosVKrtbs%3D
50. J das Neves MF Bahia 2006 Gels as vaginal drug delivery systems Int J Pharm. 318 1-2 1 14 16621366 10.1016/j.ijpharm.2006.03.012
51. J das Neves M Amiji B Sarmento 2011 Mucoadhesive nanosystems for vaginal microbicide development: friend or foe? Wiley Interdiscip Rev Nanomed Nanobiotechnol. 3 4 389 399 21506290 10.1002/wnan.144
52. das Neves J, Sarmento B, Bahia MF, Carrier RL, Amiji M. Development and characterization of dapivirine-loaded poly(ε-caprolactone) nanoparticles as novel vaginal microbicide drug delivery systems. Trends in Microbicide Formulation Workshop, 2010, Arlington, VA, USA.
53. J das Neves MF Bahia MM Amiji B Sarmento 2011 Mucoadhesive nanomedicines: characterization and modulation of mucoadhesion at the nanoscale Expert Opin Drug Deliv. 8 8 1085 1104 21599564 10.1517/17425247.2011.586334
54. A Nel S Smythe K Young K Malcolm C McCoy Z Rosenberg, et al. 2009 Safety and pharmacokinetics of dapivirine delivery from matrix and reservoir intravaginal rings to HIV-negative women J Acquir Immune Defic Syndr 51 4 416 423 19623693 10.1097/QAI.0b013e3181acb536 1:CAS:528:DC%2BD1MXotlehuro%3D
55. AM Nel P Coplan JH van de Wijgert SH Kapiga C von Mollendorf E Geubbels, et al. 2009 Safety, tolerability, and systemic absorption of dapivirine vaginal microbicide gel in healthy, HIV-negative women AIDS 23 12 1531 1538 19550287 10.1097/QAD.0b013e32832c413d 1:CAS:528:DC%2BD1MXovVSgs7k%3D